TCT 2019 | Onyx ONE: Durable Polymer vs. Polymer-Free Stent with Only One Month of Dual Antiplatelet Therapy

Courtesy of the SBHCI.

This is the first randomized study comparing a durable-polymer drug-eluting stent (zotarolimus-eluting stent Onyx) and a polymer-free drug-eluting stent (biolimus-A9-coated stent BioFreedom), with only one month of dual antiplatelet therapy in patients at high risk for bleeding.

Highlights TCT 2019

Onyx ONE was a study conducted at 84 sites that randomized 1:1 2000 total patients at high risk for bleeding. The endpoints were cardiovascular death, acute myocardial infarction, and definite or probable stent thrombosis after a 1-year follow-up.

The secondary endpoints included target-lesion restenosis, bleeding according to the BARC classification, and the separate components of the primary endpoint.


Read also: TCT 2019 | TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI.


The primary endpoint of cardiovascular death, infarction, and stent thrombosis combined at one year was 17.1% for Onyx and 16.9% for BioFreedom (p for noninferiority 0.01). The secondary endpoints and the rate for bleeding were similar for both devices.

Conclusion

Around 40% of patients who undergo angioplasty are at high risk for bleeding, and consensuses recommend 3 to 6 months of dual antiplatelet therapy for most of them, and only 1 month in very select cases. This work further supports one month of dual antiplatelet therapy and adds another device to the list (this time, one with durable polymer), a device that seems to be safe with such a short duration for dual antiplatelet therapy.

Courtesy of SBHCI.

Link to the SBHCI publication SBHCI HERE

onyx-one-tct2019

Original Title: Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT.

Author of the Original Article: Stephan Windecker.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...